7Baggers
 weekly roundup on the cannabis sector & psychedelic sector  marketexclusive.com Mon, 10 Nov 2025 14:38:12 GMT
 psychedelic: compass pathways, gh research report q3 earnings  TipRanks Thu, 06 Nov 2025 16:56:27 GMT
 psychedelic drugs market forecast 2025-2032: emerging trends,  openPR.com Thu, 06 Nov 2025 05:19:42 GMT
 compass pathways (nasdaq:cmps) shares gap up - time to buy?  MarketBeat Wed, 05 Nov 2025 18:21:30 GMT
 compass pathways plc (nasdaq:cmps) q3 2025 earnings call transcript  Insider Monkey Wed, 05 Nov 2025 08:00:00 GMT
 compass pathways earnings call highlights progress and plans  TipRanks Wed, 05 Nov 2025 00:26:26 GMT
 COMPASS Pathways : investor presentation November 2025  MarketScreener Tue, 04 Nov 2025 14:33:06 GMT
 Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months  Psychedelic Alpha Tue, 04 Nov 2025 11:54:32 GMT
 COMPASS Pathways plc SEC 10-Q Report  TradingView Tue, 04 Nov 2025 11:33:00 GMT
 Compass Pathways Earnings Call Highlights Progress and Plans  TipRanks Tue, 04 Nov 2025 08:00:00 GMT
 compass pathways, neurokaire enter r&d collaboration  TipRanks Thu, 30 Oct 2025 14:29:56 GMT

COMPASS Pathways plc
(NASDAQ:CMPS) 

CMPS stock logo

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation, which is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited a...

Founded: 2016
CEO: George Goldsmith  
Sector: Other
Industry: Other

Share this website to your friends